DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 01/17/2019 --DelveInsight has announced the addition of the "Major Depressive Disorder (MDD)- Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

Report provides an overview of the disease and market size of MDD for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and MDD forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Major depressive disorder also referred to as depression, is a serious medical illness that disrupts a person's mood, behaviour, thought processes, and physical health. It should not be mistaken for the passing feelings of unhappiness that everyone experiences, nor should it be confused with the intense grief brought about by the death of a loved one. A major depressive episode is characterized by at least two weeks of depressed mood or loss of interest and accompanied by at least four more symptoms of depression. Depression does not have a single cause. It can be triggered, or it may occur spontaneously without being associated with a life crisis, physical illness or other risks. Various factors that contribute to depression include trauma, genetics, brain structure, and other medical conditions. Major depressive disorder is segmented into subgroups includes psychotic depression, melancholic depression, atypical depression, postpartum depression, postpartum psychosis, and seasonal affective disorder. The patient pool of female was more as compared to male as per DelveInsight's Report.

DelveInsight estimates suggest that there were approximately 34,011,712 12 months prevalent cases of Major Depressive Disorder in 2016 in 7MM. These prevalent cases are further expected to increase by 2027. The United States accounts for the highest prevalent population of Major Depressive Disorder, followed by EU5 and Japan. Among the European countries, France had the highest 12 months prevalent population of Major Depressive Disorder with 3,346,450 cases, followed by Germany which had prevalent population of 2,291,202 in 2016. On the other hand, UK had the lowest 12 months prevalent population of 1,484,679 cases in 2016. Japan has 2,933,577 12 months prevalent cases of Major Depressive Disorder in 2016.

According to DelveInsight, in 2016, 619,335 Pediatrics (7-11 yr.), 3,100,000 adolescents (12-17 yr.) and 16,733,057 adults (18 yr. & older) has experienced major depressive episode in the United States. Prevalent population of Major Depressive Disorder in 7MM is expected to increase at a CAGR of 4.9% for the study period i.e. 2016-2027. Among EU5 countries, France had the highest market size with USD 1.0 billion in 2016 and capturing 31.9% of the EU5 market share by 2027, followed by Germany with USD 0.7 billion in 2016.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027

Drug Companies

1. Axsome Therapeutics
2. Alkermes
3. Fabre-Kramer Pharmaceuticals
4. SAGE therapeutics
5. Janssen Pharmaceuticals
And many others

Drugs covered

1. AXS-05
2. ALKS-5461
3. Travivo
4. SAGE-217
5. Esketamine Nasal Spray
And many others

Report Scope

The report covers a descriptive overview of the MDD, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the MDD and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for MDD are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted MDD market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global MDD market.